帕金森病预防试验应招募谁?基因高风险队列的理由
本文综述了基因分层队列(如LRRK2和GBA1)在帕金森病一级和二级预防试验中的优势与挑战。作者认为基因分层可减少疾病异质性、提供特定终点和生物标志物,但存在遗传变异异质性、外显率降低及招募达标困难等问题,并提出了利用这些优势的建议。
要点
- 基因分层队列可减少帕金森病异质性,提供特定临床特征、机制和生物标志物。
- 挑战包括遗传变异异质性、外显率降低导致许多携带者不发病、招募达标困难。
- 作者建议利用基因分层队列的优势来推进帕金森病预防试验。
核心结论
- 基因分层队列为帕金森病预防试验提供了诸多优势,但面临遗传变异异质性、外显率降低和招募困难等挑战,作者提出了利用这些优势的建议。
研究设计与样本
- 综述,讨论将基因分层队列(如富含亮氨酸重复激酶2和葡萄糖脑苷脂酶1)纳入预防试验的机会与挑战,主要关注一级预防试验。
主要发现
- 基因分层队列易于识别,并在多个层面减少疾病异质性,包含表型和病理学富集的人群,具有明确的临床特征、致病机制和相关蛋白,可作为试验终点、治疗靶点和生物标志物。
- 挑战来自遗传变异异质性、外显率降低导致许多携带者不会发展为帕金森病,以及在拟议研究期内招募到符合预期结局的人群存在困难。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapies that prevent the occurrence of Parkinson disease (PD) (primary prevention) or mitigate the progression of symptoms in those with early disease (secondary prevention) are a critical unmet need in disease management. Despite great promise, PD prevention trials have not yet demonstrated success. Initiation of treatment too late in the disease course and the heterogeneity of disease are obstacles that may have contributed to the failure. Genetically stratified groups offer many advantages to primary and secondary prevention trials. In addition to their ease of identification, they decrease disease heterogeneity on several levels. Particularly, they comprise a phenotypically and pathologically enriched group with defined clinical features, pathogenic mechanisms and associated proteins that may serve as specific trial endpoints, therapeutic targets and biomarkers for disease state, and pharmacodynamic and pharmacokinetic status. However, challenges arise from genetic variant heterogeneity, from reduced penetrance whereby many carriers will not develop PD, and in recruiting a population that will meet the desired outcome in the proposed study duration. In this review, we discussed the opportunities afforded by the enrollment of genetically stratified cohorts (i.e., leucine-rich repeat kinase 2 and glucocerebrosidase 1) into prevention trials with a primary focus on primary prevention trials. We also outlined challenges surrounding the enrollment of these cohorts and offered suggestions to leverage their many advantages.
引用
- Niotis K, West AB, Saunders-Pullman R, et al. Who to Enroll in Parkinson Disease Prevention Trials? The Case for Genetically At-Risk Cohorts. Neurology. 2022. PMID: 35970585. doi:10.1212/WNL.0000000000200812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。